Ren Le, Yu Yue
Department of Gastroenterology, Affiliated Provincial Hospital, Anhui Medical University, Hefei, China.
Ther Clin Risk Manag. 2018 Jan 25;14:179-187. doi: 10.2147/TCRM.S154226. eCollection 2018.
Pancreatic ductal adenocarcinoma (PDAC) remains a very challenging malignancy with late presentation, metastatic potential, chemoresistance, and poor prognosis. Therefore, there is an urgent need for novel diagnostic and prognostic biomarkers. miRNAs are small noncoding RNAs that regulate the expression of multitude number of genes. Aberrant expression of miRNAs has been linked to the development of various malignancies, including PDAC. A series of miRNAs have been defined as holding promise for early diagnostics, as indicators of therapy resistance, and even as markers for prognosis in PDAC patients. In this review, we summarize the current knowledge on the role of miRNAs in diagnosis, chemoresistance, and prognosis in PDAC patients.
胰腺导管腺癌（PDAC）仍然是一种极具挑战性的恶性肿瘤，具有出现较晚、转移潜能、化疗耐药性和预后较差等特点。因此，迫切需要新的诊断和预后生物标志物。微小RNA（miRNAs）是一类小的非编码RNA，可调节众多基因的表达。miRNAs的异常表达与包括PDAC在内的各种恶性肿瘤的发生发展有关。一系列miRNAs已被确定有望用于早期诊断、作为治疗耐药性的指标，甚至作为PDAC患者预后的标志物。在本综述中，我们总结了目前关于miRNAs在PDAC患者诊断、化疗耐药性和预后方面作用的知识。
